Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

被引：36

作者：

Rosenberg, J. E. ^{[1
]}

Milowsky, M. ^{[2
]}

Ramamurthy, C. ^{[3
]}

Mar, N. ^{[4
]}

Mckay, R. R. ^{[5
]}

Friedlander, T. ^{[6
]}

Ferrario, C. ^{[7
]}

Bracarda, S. ^{[8
]}

George, S. ^{[9
]}

Moon, H. ^{[10
]}

Geynisman, D. ^{[11
]}

Petrylak, D. P. ^{[12
]}

Borchiellini, D. ^{[13
]}

Burgess, E. F. ^{[14
]}

Rey, J. P. Maroto ^{[15
]}

Carret, A-S. ^{[16
]}

Yu, Y. ^{[17
]}

Guseva, M. V. ^{[18
]}

Moreno, B. Homet ^{[19
]}

O'Donnell, P. H. ^{[20
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Med Dept, New York, NY USA

[2] Univ North Carolina Chapel Hill, Med Dept, Chapel Hill, NC USA

[3] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Hematol, San Antonio, TX USA

[4] Univ Calif Irvine, UCI Hlth, Hematol Oncol, Orange, CA USA

[5] Univ Calif San Diego, Med Oncol, La Jolla, CA USA

[6] UCSF Univ Calif San Francisco, Oncol, San Francisco, CA USA

[7] Jewish Gen Hosp, Oncol, Montreal, PQ, Canada

[8] Azienda Osped Santa Maria, Med Translat Oncol Unit, Terni, Italy

[9] Roswell Pk Comprehens Canc Ctr, Med Dept, Buffalo, NY USA

[10] Kaiser Permanente Riverside Med Ctr, Oncol Dept, Riverside, CA USA

[11] Fox Chase Canc Ctr, Med Oncol Dept, Main Campus, Philadelphia, PA USA

[12] Yale Univ, Med Oncol Dept, Sch Med, New Heaven, CT USA

[13] Ctr Antoine Lacassagne, Oncol, Nice, France

[14] Levine Canc Inst, Dept Med Oncol, Charlotte, NC USA

[15] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[16] Seagen Inc, Clin Dev, Bothell, WA USA

[17] Seagen Inc, Biostat, Bothell, WA USA

[18] Astellas Pharma USA, Oncol, Global Medica Affairs, Northbrook, IL USA

[19] Merck & Co Inc, Clin Res, Rahway, NJ USA

[20] Univ Chicago, Hematol & Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.08.079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA73

引用

页码：S1441 / S1441

页数：1

共 50 条

[1] Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.
O'Donnell, Peter H.
Rosenberg, Jonathan E.
Hoimes, Christopher J.
Petrylak, Daniel P.
Milowsky, Matthew I.
Mckay, Rana R.
Srinivas, Sandy
Friedlander, Terence W.
Ramamurthy, Chethan
Bilen, Mehmet Asim
Burgess, Earle F.
Mar, Nataliya
Moon, Helen
Geynisman, Daniel M.
George, Saby
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Flaig, Thomas W.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[2] Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.
Milowsky, Matthew I.
O'Donnell, Peter H.
Hoimes, Christopher J.
Petrylak, Daniel P.
Flaig, Thomas W.
Moon, Helen H.
Friedlander, Terence W.
Mar, Nataliya
McKay, Rana R.
Srinivas, Sandy
Gravis, Gwenaelle
Ramamurthy, Chethan
Bupathi, Manojkumar
Bracarda, Sergio
Wright, Phoebe
Carret, Anne-Sophie
Yu, Yao
Matsuda, Tara
Kataria, Ritesh S.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[3] Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
O'Donnell, Peter H.
Milowsky, Matthew I.
Petrylak, Daniel P.
Hoimes, Christopher J.
Flaig, Thomas W.
Mar, Nataliya
Moon, Helen H.
Friedlander, Terence W.
McKay, Rana R.
Bilen, Mehmet A.
Srinivas, Sandy
Burgess, Earle F.
Ramamurthy, Chethan
George, Saby
Geynisman, Daniel M.
Bracarda, Sergio
Borchiellini, Delphine
Geoffrois, Lionnel
Rey, Jose Pablo Maroto
Ferrario, Christiano
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Moreno, Blanca Homet
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4107 - +
[4] Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
Mar, Nataliya
Friedlander, Terence W.
Hoimes, Christopher J.
Flaig, Thomas W.
Bilen, Mehmet Asim
Balar, Arjun Vasant
Henry, Elizabeth
Srinivas, Sandy
Rosenberg, Jonathan E.
Petrylak, Daniel Peter
Burgess, Earle Frederick
Merchan, Jaime R.
Tagawa, Scott T.
Carret, Anne-Sophie
Steinberg, Joyce Leta
Chaney, Marya F.
Milowsky, Matthew, I
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.
Friedlander, Terence W.
Milowsky, Matthew I.
O'Donnell, Peter H.
Petrylak, Daniel P.
Hoimes, Christopher J.
Flaig, Thomas W.
Mar, Nataliya
Moon, Helen H.
McKay, Rana R.
Bilen, Mehmet Asim
Borchiellini, Delphine
Iafolla, Marco
Carret, Anne-Sophie
Yu, Yao
Guseva, Maria
Kataria, Ritesh S.
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
Hoimes, Christopher J.
Rosenberg, Jonathan E.
Petrylak, Daniel Peter
Carret, Anne-Sophie
Melhem-Bertrandt, Amal
Flaig, Thomas W.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[7] The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial
Hoimes, Christopher J.
Rosenberg, Jonathan E.
Petrylak, Daniel P.
Carret, Anne-Sophie
Melhem-Bertrandt, Amal
Flaig, Thomas W.
CLINICAL CANCER RESEARCH, 2020, 26 (15) : 43 - 43
[8] EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Hoimes, C. J.
Rosenberg, J. E.
Srinivas, S.
Petrylak, D. P.
Milowsky, M.
Merchan, J. R.
Bilen, M. A.
Gupta, S.
Carret, A-S.
Yuan, N.
Melhem-Bertrandt, A.
Flaig, T.
ANNALS OF ONCOLOGY, 2019, 30 : 356 - 356
[9] Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
Rosenberg, Jonathan E.
Flaig, Thomas W.
Friedlander, Terence W.
Milowsky, Matthew I.
Srinivas, Sandy
Petrylak, Daniel Peter
Merchan, Jaime R.
Bilen, Mehmet Asim
Carret, Anne-Sophie
Yuan, Nancy
Sasse, Carolyn
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Rosenberg, Jonathan E.
Flaig, Thomas W.
Friedlander, Terence W.
Milowsky, Matthew, I
Srinivas, Sandy
Petrylak, Daniel Peter
Merchan, Jaime R.
Bilen, Mehmet Asim
Carret, Anne-Sophie
Yuan, Nancy
Sasse, Carolyn
Hoimes, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →